• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Viking Thera (NQ: VKTX )

    50.90 +0.80 (+1.60%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,885,594
    Open 49.94
    Bid (Size) 50.81 (4)
    Ask (Size) 51.30 (2)
    Prev. Close 50.10
    Today's Range 49.75 - 52.34
    52wk Range 8.280 - 99.41
    Shares Outstanding 99,581,693
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    3 Monster Stocks in the Making to Buy Right Now
    They're small now, but these stocks could grow much larger. 
    Via The Motley Fool
    Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
    The Nasdaq tumbled amid chip woes. 
    Via Investor's Business Daily

    Performance

    YTD
    +178.45%
    +178.45%
    1 Month
    +0.93%
    +0.93%
    3 Month
    -19.74%
    -19.74%
    6 Month
    +133.81%
    +133.81%
    1 Year
    +234.87%
    +234.87%

    More News

    Read More
    3 Undervalued Biotech Stocks With Breakout Potential
    Via InvestorPlace
    Is Viking Therapeutics a Millionaire-Maker?
    Via The Motley Fool
    Smart Money Is Betting Big In VKTX Options
    Via Benzinga
    Spotlight on Viking Therapeutics: Analyzing the Surge in Options Activity
    Via Benzinga
    EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
    Via Benzinga
    3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition
    Via InvestorPlace
    Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
    Via Benzinga
    Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There'
    Via Benzinga
    Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Eli Lilly, Novo Nordisk Fall As Roche Releases Weight-Loss Drug Data
    Via Investor's Business Daily
    Is Viking Therapeutics the Best Biotech Stock for You?
    Via The Motley Fool
    The 3 Most Undervalued Biotech Stocks to Buy in July 2024
    Via InvestorPlace
    Is Viking Therapeutics Stock Running Out of Steam?
    Via The Motley Fool
    Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics
    Via The Motley Fool
    Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
    Via MarketBeat
    Eli Lilly Rose More Than 50% So Far This Year. Can It Soar Past $1,000 in the 2nd Half?
    Via The Motley Fool
    3 Overlooked Giants-in-the-Making for Patient Investors
    Via InvestorPlace
    The 7 Best Under $10 Stocks to Buy in July 2024
    Via InvestorPlace
    Forget Eli Lilly: 3 Biotech Stocks to Buy Instead
    Via The Motley Fool
    S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
    Via Benzinga
    Topics Economy Stocks
    Exposures Interest Rates US Equities
    3 Biotech Moonshots With Imminent Catalyst Potential
    Via InvestorPlace
    Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
    Via MarketBeat
    Exposures Product Safety
    Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
    Via MarketBeat
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.